AgingResearch.NewsJoin free

Kookmin Bio

CompanySouth Korea

Kookmin Bio develops 2 assets, the furthest in clinical trials with no phase (KL-001 in sarcopenia). Mostly microbiome; based in South Korea.

2
Assets
Furthest stage
Clinical, no phase
0
Trials
3
Signals

Pipeline

2

  • KL-001

    Postbiotic based on Lactiplantibacillus plantarum KM2 intended to improve muscle strength.

    Clinical, no phase, Microbiome, sarcopenia

  • KMBR-001

    Stage not known, Microbiome

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Signals3
  • Similar companies6

Intelligence